Recent results of basic and clinical research in MEN1: opportunities to improve early detection and treatment

References

• Dreijerink KM, Höppener JW, Timmers HM, Lips CJ. Mechanisms of disease: multiple endocrine neoplasia Type 1 –relation to chromatin modifications and transcription regulation. Nat. Clin. Pract. Endocrinol. Metab. 2(10), 562–570 (2006).
   PubMedGoogle Scholar
• Wu T, Hua X. Menin represses tumorigenesis via repressing cell proliferation. Am. J. Cancer Res. 1(6), 726–739 (2011).
   PubMedGoogle Scholar
• Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum. Mutat. 29(1), 22–32 (2008).
   PubMed Web of Science ®Google Scholar
• Conte-Devolx B, Niccoli P; Groupe d’étude des Tumeurs Endocrines. [Clinical characteristics of multiple endocrine neoplasia]. Bull. Acad. Natl Med. 194(1), 69–78; discussion 78 (2010).
   PubMedGoogle Scholar
• Murai MJ, Chruszcz M, Reddy G, Grembecka J, Cierpicki T. Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein. J. Biol. Chem. 286(36), 31742–31748 (2011).
   PubMedGoogle Scholar
• Huang J, Gurung B, Wan B et al. The same pocket in menin binds both MML and JunD but has opposite effects on transcription. Nature 482(7386), 542–546 (2012).
   PubMed Web of Science ®Google Scholar
• Osz J, Brélivet Y, Peluso-Iltis C et al. Structural basis for a molecular allosteric control mechanism of cofactor binding to nuclear receptors. Proc. Natl Acad. Sci. USA 109(10), E588–E594 (2012).
   Web of Science ®Google Scholar
• Zhang HL, Li WY, Zhang CP et al. Differentially expressed genes in Men1 knockout and wild-type embryoid bodies for pancreatic islet development. Mol. Med. Report. 4(2), 301–305 (2011).
   PubMedGoogle Scholar
• Hughes CM, Rozenblatt-Rosen O, Milne TA et al. Menin associates with a trithorax family histone methyltransferase complex and with the HOXC8 locus. Mol. Cell 13(4), 587–597 (2004).
   PubMed Web of Science ®Google Scholar
• Milne TA, Hughes CM, Lloyd R et al. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc. Natl Acad. Sci. USA 102(3), 749–754 (2005).
   PubMed Web of Science ®Google Scholar
• Lin SY, Elledge SJ. Multiple tumor suppressor pathways negatively regulate telomerase. Cell 113(7), 881–889 (2003).
   PubMed Web of Science ®Google Scholar
• Taguchi R, Yamada M, Horiguchi K et al. Haploinsufficient and predominant expression of multiple endocrine neoplasia type 1 (MEN1)-related genes, MLL, p27Kip1 and p18Ink4C in endocrine organs. Biochem. Biophys. Res. Commun. 415(2), 378–383 (2011).
   PubMedGoogle Scholar
• Hou R, Manwaring LP, Moley JF, Whelan A. A novel missense mutation in Men1 gene in a family with multiple endocrine neoplasia type I. Endocr. Pract. 31, 1–14 (2011).
   Google Scholar
• Vierimaa O, Ebeling TM, Kytölä S et al. Multiple endocrine neoplasia type 1 in northern Finland; clinical features and genotype phenotype correlation. Eur. J. Endocrinol. 157(3), 285–294 (2007).
   PubMedGoogle Scholar
• Bazzi W, Renon M, Vercherat C et al. MEN1 missense mutations impair sensitization to apoptosis induced by wild-type menin in endocrine pancreatic tumor cells. Gastroenterology 135(5), 1698–1709.e2 (2008).
   PubMedGoogle Scholar
• Yaguchi H, Ohkura N, Takahashi M, Nagamura Y, Kitabayashi I, Tsukada T. Menin missense mutants associated with multiple endocrine neoplasia type 1 are rapidly degraded via the ubiquitin –proteasome pathway. Mol. Cell. Biol. 24(15), 6569–6580 (2004).
   PubMedGoogle Scholar
• Canaff L, Vanbellinghen JF, Kanazawa I et al. Menin missense mutants encoded by the MEN1 gene that are targeted to the proteasome: restoration of expression and activity by CHIP siRNA. J. Clin. Endocrinol. Metab. 97(2), E282–E291 (2012).
   Google Scholar
• Shimazu S, Nagamura Y, Yaguchi H, Ohkura N, Tsukada T. Correlation of mutant menin stability with clinical expression of multiple endocrine neoplasia type 1 and its incomplete forms. Cancer Sci. 102(11), 2097–2102 (2011).
   PubMedGoogle Scholar
• Lips CJ, Dreijerink KM, Höpppener JW. Variable clinical expression in patients with a germline MEN1-disease gene mutation: clues for a genotype – phenotype correlation. Clinics (2012) (In Press).
   PubMedGoogle Scholar
• Drori-Herishanu L, Horvath A, Nesterova M et al. An intronic mutation is associated with prolactinoma in a young boy, decreased penetrance in his large family, and variable effects on MEN1 mRNA and protein. Horm. Metab. Res. 41(8), 630–634 (2009).
   PubMedGoogle Scholar
• Agarwal SK, Ozawa A, Mateo CM, Marx SJ. The MEN1 gene and pituitary tumours. Horm. Res. 71(Suppl. 2), 131–138 (2009).
   PubMedGoogle Scholar
• Olufemi SE, Green JS, Manickam P et al. Common ancestral mutation in the MEN1 gene is likely responsible for the prolactinoma variant of MEN1 (MEN1Burin) in four kindreds from Newfoundland. Hum. Mutat. 11(4), 264–269 (1998).
   PubMed Web of Science ®Google Scholar
• Kong C, Ellard S, Johnston C, Farid NR. Multiple endocrine neoplasia type 1Burin from Mauritius: a novel MEN1 mutation. J. Endocrinol. Invest. 24(10), 806–810 (2001).
   PubMedGoogle Scholar
• Lourenço DM Jr, Toledo RA, Mackowiak II et al. Multiple endocrine neoplasia type 1 in Brazil: MEN1 founding mutation, clinical features, and bone mineral density profile. Eur. J. Endocrinol. 159(3), 259–274 (2008).
   PubMedGoogle Scholar
• Hannan FM, Nesbit MA, Christie PT et al. Familial isolated primary hyperparathyroidism caused by mutations of the MEN1 gene. Nat. Clin. Pract. Endocrinol. Metab. 4(1), 53–58 (2008).
   PubMedGoogle Scholar
• Schaaf L, Pickel J, Zinner K et al. Developing effective screening strategies in multiple endocrine neoplasia type 1 (MEN1) on the basis of clinical and sequencing data of German patients with MEN 1. Exp. Clin. Endocrinol. Diabetes 115(8), 509–517 (2007).
   PubMedGoogle Scholar
• Raef H, Zou M, Baitei EY et al. A novel deletion of the MEN1 gene in a large family of multiple endocrine neoplasia type 1 (MEN1) with aggressive phenotype. Clin. Endocrinol. 75(6), 791–800 (2011).
   PubMedGoogle Scholar
• Hasani-Ranjbar S, Amoli MM, Ebrahim-Habibi A et al. A new frameshift MEN1 gene mutation associated with familial malignant insulinomas. Fam. Cancer 10(2), 343–348 (2011).
   PubMedGoogle Scholar
• Dreijerink KM, Mulder KW, Winkler GS, Höppener JW, Lips CJ, Timmers HT. Menin links estrogen receptor activation to histone H3K4 trimethylation. Cancer Res. 66(9), 4929–4935 (2006).
   PubMedGoogle Scholar
• Goudet P, Bonithon-Kopp C, Murat A et al. Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d'Etude des Tumeurs Endocrines. Eur. J. Endocrinol. 165(1), 97–105 (2011).
   PubMedGoogle Scholar
• Sakurai A, Suzuki S, Kosugi S et al.; MEN Consortium of Japan. Multiple endocrine neoplasia type 1 in Japan: establishment and analysis of a multicentre database. Clin. Endocrinol. 76(4), 533–539 (2011).
   Google Scholar
• Vierimaa O, Georgitsi M, Lehtonen R et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312(5777), 1228–1230 (2006).
   PubMed Web of Science ®Google Scholar
• Karhu A, Aaltonen LA. Susceptibility to pituitary neoplasia related to MEN-1, CDKN1B and AIP mutations: an update. Hum. Mol. Genet. 16(Spec No 1), R73–R79 (2007).
   PubMed Web of Science ®Google Scholar
• Georgitsi M, Heliövaara E, Paschke R et al. Large genomic deletions in AIP in pituitary adenoma predisposition. J. Clin. Endocrinol. Metab. 93(10), 4146–4151 (2008).
   PubMed Web of Science ®Google Scholar
• Occhi G, Trivellin G, Ceccato F et al. Prevalence of AIP mutations in a large series of sporadic Italian acromegalic patients and evaluation of CDKN1B status in acromegalic patients with multiple endocrine neoplasia. Eur. J. Endocrinol. 163(3), 369–376 (2010).
   PubMed Web of Science ®Google Scholar
• Belar O, De la Hoz C, Pérez-Nanclares G, Castaño L, Gaztambide S; Spanish MEN1 Group. Novel mutations in Men1, CDKN1b and AIP genes in patients with multiple endocrine neoplasia type 1 syndrome in Spain. Clin. Endocrinol. doi:10.1111/j.1365-2265.2011.04269.x (2012) (Epub ahead of print).
   PubMedGoogle Scholar
• Laconi E. The evolving concept of tumor microenvironments. Bioessays 29(8), 738–744 (2007).
   PubMedGoogle Scholar
• Dreijerink KM, Varier RA, van Nuland R et al. Regulation of vitamin D receptor function in MEN1-related parathyroid adenomas. Mol. Cell. Endocrinol. 313(1–2), 1–8 (2009).
   PubMedGoogle Scholar
• van Veelen W, van Gasteren CJ, Acton DS et al. Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development. Cancer Res. 68(5), 1329–1337 (2008).
   PubMed Web of Science ®Google Scholar
• van Veelen W, Klompmaker R, Gloerich M et al. p18 is a tumor suppressor gene involved in human medullary thyroid carcinoma and pheochromocytoma development. Int. J. Cancer 124(2), 339–345 (2009).
   PubMedGoogle Scholar
• Pellegata NS, Quintanilla-Martinez L, Siggelkow H et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc. Natl Acad. Sci. USA 103(42), 15558–15563 (2006); erratum in: 103, 19213 (2006).
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Mateo CM, Marx SJ. Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J. Clin. Endocrinol. Metab. 94(5), 1826–1834 (2009); comment in: 94, 1518–1520 (2009).
   PubMed Web of Science ®Google Scholar
• Owens M, Stals K, Ellard S, Vaidya B. Germline mutations in the CDKN1B gene encoding p27 Kip1 are a rare cause of multiple endocrine neoplasia type 1. Clin. Endocrinol. 70(3), 499–500 (2009).
   PubMedGoogle Scholar
• Igreja S, Chahal HS, Akker SA et al. Assessment of p27 (cyclin-dependent kinase inhibitor 1B) and aryl hydrocarbon receptor-interacting protein (AIP) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable MEN1 gene mutations. Clin. Endocrinol. 70(2), 259–264 (2009).
   PubMedGoogle Scholar
• Bai F, Pei XH, Nishikawa T, Smith MD, Xiong Y. p18Ink4c, but not p27Kip1, collaborates with Men1 to suppress neuroendocrine organ tumors. Mol. Cell. Biol. 27(4), 1495–1504 (2007).
   PubMedGoogle Scholar
• Molatore S, Pellegata NS. The MENX syndrome and p27: relationships with multiple endocrine neoplasia. Prog. Brain Res. 182, 295–320 (2010).
   PubMedGoogle Scholar
• Marinoni I, Pellegata NS. p27kip1: a new multiple endocrine neoplasia gene? Neuroendocrinology 93(1), 19–28 (2011).
   PubMedGoogle Scholar
• Christopoulos C, Balatsos V, Rotas E et al. The syndrome of gastric carcinoid and hyperparathyroidism: a family study and literature review. Eur. J. Endocrinol. 160(4), 689–694 (2009).
   PubMedGoogle Scholar
• Davenport C, Agha A. The role of menin in parathyroid tumorigenesis. Adv. Exp. Med. Biol. 668, 79–86 (2009).
   PubMedGoogle Scholar
• Costa-Guda J, Marinoni I, Molatore S, Pellegata NS, Arnold A. Somatic mutation and germline sequence abnormalities in CDKN1B, encoding p27Kip1, in sporadic parathyroid adenomas. J. Clin. Endocrinol. Metab. 96(4), E701–E706 (2011).
   Google Scholar
• Dworakowska D, Grossman AB. The pathophysiology of pituitary adenomas. Best Pract. Res. Clin. Endocrinol. Metab. 23, 525–541 (2009).
   PubMedGoogle Scholar
• Seoane S, Perez-Fernandez R. The vitamin D receptor represses transcription of the pituitary transcription factor Pit-1 gene without involvement of the retinoid X receptor. Mol. Endocrinol. 20(4), 735–748 (2006).
   PubMedGoogle Scholar
• Lacerte A, Lee EH, Reynaud R et al. Activin inhibits pituitary prolactin expression and cell growth through Smads, Pit-1 and menin. Mol. Endocrinol. 18(6), 1558–1569 (2004).
   PubMedGoogle Scholar
• Lebrun JJ. Activin, TGF-beta and menin in pituitary tumorigenesis. Adv. Exp. Med. Biol. 668, 69–78 (2009).
   PubMedGoogle Scholar
• Jiao Y, Shi C, Edil BH et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331(6021), 1199–1203 (2011); comment in: 331, 1145–1146 (2011).
   PubMed Web of Science ®Google Scholar
• Wang Y, Ozawa A, Zaman S et al. The tumor suppressor protein menin inhibits AKT activation by regulating its cellular localization. Cancer Res. 71(2), 371–382 (2011).
   PubMed Web of Science ®Google Scholar
• Chen G, Jingbo A, Wang M et al. Menin promotes the Wnt signaling pathway in pancreatic endocrine cells. Mol. Cancer Res. 6, 1894–1907 (2008).
   PubMedGoogle Scholar
• Ishida E, Yamada M, Horiguchi K et al. Attenuated expression of menin and p27 (Kip1) in an aggressive case of multiple endocrine neoplasia type 1 (MEN1) associated with an atypical prolactinoma and a malignant pancreatic endocrine tumor. Endocr. J. 58(4), 287–296 (2011).
   PubMedGoogle Scholar
• Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 6(3), 184–192 (2006).
   PubMed Web of Science ®Google Scholar
• Pitt SC, Chen H, Kunnimalaiyaan M. Inhibition of phosphatidylinositol 3-kinase/Akt signaling suppresses tumor cell proliferation and neuroendocrine marker expression in GI carcinoid tumors. Ann. Surg. Oncol. 16(10), 2936–2942 (2009).
   PubMedGoogle Scholar
• Kim YS, Burns AL, Goldsmith PK et al. Stable overexpression of MEN1 suppresses tumorigenicity of RAS. Oncogene 18(43), 5936–5942 (1999).
   PubMedGoogle Scholar
• Marx SJ, Simonds WF. Hereditary hormone excess: genes, molecular pathways, and syndromes. Endocr. Rev. 26(5), 615–661 (2005).
   PubMedGoogle Scholar
• Norton JA, Venzon DJ, Berna MJ et al. Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger–Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann. Surg. 247(3), 501–510 (2008).
   PubMed Web of Science ®Google Scholar
• Davì MV, Boninsegna L, Dalle Carbonare L et al. Presentation and outcome of pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1 syndrome. Neuroendocrinology 94(1), 58–65 (2011).
   PubMedGoogle Scholar
• Schreinemakers JM, Pieterman CR, Scholten A, Vriens MR, Valk GD, Rinkes IH. The optimal surgical treatment for primary hyperparathyroidism in MEN1 patients: a systematic review. World J. Surg. 35(9), 1993–2005 (2011).
   PubMedGoogle Scholar
• Salmeron MD, Gonzalez JM, Sancho Insenser J et al. Causes and treatment of recurrent hyperparathyroidism after subtotal parathyroidectomy in the presence of multiple endocrine neoplasia 1. World J. Surg. 34(6), 1325–1331 (2010).
   PubMedGoogle Scholar
• Borot S, Lapierre V, Carnaille B, Goudet P, Penfornis A. Results of cryopreserved parathyroid autografts: a retrospective multicenter study. Surgery 147(4), 529–535 (2010).
   PubMedGoogle Scholar
• Moyes VJ, Monson JP, Chew SL, Akker SA. Clinical use of cinacalcet in MEN1 hyperparathyroidism. Int. J. Endocrinol. 2010, 906163 (2010).
   PubMed Web of Science ®Google Scholar
• Lévy-Bohbot N, Merle C, Goudet P et al.; Groupe des Tumeurs Endocrines. Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol. Clin. Biol. 28(11), 1075–1081 (2004).
   PubMedGoogle Scholar
• Anlauf M, Schlenger R, Perren A et al. Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am. J. Surg. Pathol. 30(5), 560–574 (2006).
   PubMed Web of Science ®Google Scholar
• Akerström G, Hessman O, Hellman P, Skogseid B. Pancreatic tumours as part of the MEN-1 syndrome. Best Pract. Res. Clin. Gastroenterol. 19(5), 819–830 (2005).
   PubMed Web of Science ®Google Scholar
• Thomas-Marques L, Murat A, Delemer B et al.; Groupe des Tumeurs Endocrines (GTE). Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am. J. Gastroenterol. 101(2), 266–273 (2006).
   PubMed Web of Science ®Google Scholar
• Fiebrich HB, van Asselt SJ, Brouwers AH et al. Tailored imaging of islet cell tumors of the pancreas amidst increasing options. Crit. Rev. Oncol. Hematol. doi:10.1016/j.critrevonc.2011.05.006 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Barbe C, Murat A, Dupas B et al. for the Groupe d’étude des Tumeurs Endocrines (GTE). Magnetic resonance imaging versus endoscopic ultrasonography for the detection of pancreatic tumours in multiple endocrine neoplasia type 1. Dig. Liver Dis. 44(3), 228–234 (2011)
   PubMedGoogle Scholar
• Koopmans KP, Neels OC, Kema IP et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J. Clin. Oncol. 26(9), 1489–1495 (2008).
   PubMed Web of Science ®Google Scholar
• Tessonnier L, Sebag F, Ghander C et al. Limited value of 18F-F-DOPA PET to localize pancreatic insulin-secreting tumors in adults with hyperinsulinemic hypoglycemia. J. Clin. Endocrinol. Metab. 95(1), 303–307 (2010).
   PubMedGoogle Scholar
• Tonelli F, Fratini G, Falchetti A, Nesi G, Brandi ML. Surgery for gastroenteropancreatic tumours in multiple endocrine neoplasia type 1: review and personal experience. J. Intern. Med. 257(1), 38–49 (2005).
   PubMedGoogle Scholar
• Bartsch DK, Fendrich V, Langer P, Celik I, Kann PH, Rothmund M. Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann. Surg. 242(6), 757–764; discussion 764–766 (2005).
   PubMedGoogle Scholar
• Tonelli F, Giudici F, Fratini G, Brandi ML. Pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: review of literature. Endocr. Pract. 17(Suppl. 3), 33–40 (2011).
   PubMedGoogle Scholar
• Imamura M, Komoto I, Ota S et al. Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients. World J. Gastroenterol. 17(10), 1343–1353 (2011).
   PubMedGoogle Scholar
• Gauger PG, Doherty GM, Broome JT, Miller BS, Thompson NW. Completion pancreatectomy and duodenectomy for recurrent MEN-1 pancreaticoduodenal endocrine neoplasms. Surgery 146(4), 801–806; discussion 807 (2009).
   PubMedGoogle Scholar
• Norton JA, Harris EJ, Chen Y et al. Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Arch. Surg. 146(6), 724–732 (2011).
   PubMedGoogle Scholar
• Huang LC, Poultsides GA, Norton JA. Surgical management of neuroendocrine tumors of the gastrointestinal tract. Oncology 25(9), 794–803 (2011).
   PubMedGoogle Scholar
• Burns WR, Edil BH. Neuroendocrine pancreatic tumors: guidelines for management and update. Curr. Treat. Options Oncol. 13(1), 24–34 (2012).
   PubMed Web of Science ®Google Scholar
• Biermasz NR, Smit JW, Pereira AM, Frölich M, Romijn JA, Roelfsema F. Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients. Pituitary 10(3), 237–249 (2007).
   PubMedGoogle Scholar
• Weiss DE, Vogel H, Lopes MB, Chang SD, Katznelson L. Ectopic acromegaly due to a pancreatic neuroendocrine tumor producing growth hormone-releasing hormone. Endocr. Pract. 17(1), 79–84 (2011).
   PubMedGoogle Scholar
• Vergès B, Boureille F, Goudet P et al. Pituitary disease in MEN type 1 (MEN1): data from the France – Belgium MEN1 multicenter study. J. Clin. Endocrinol. Metab. 87(2), 457–465 (2002).
   PubMed Web of Science ®Google Scholar
• Simonds WF, Varghese S, Marx SJ, Nieman LK. Cushing's syndrome in multiple endocrine neoplasia type 1. Clin. Endocrinol. 76(3), 379–386 (2012).
   PubMedGoogle Scholar
• Feelders RA, de Bruin C, Pereira AM et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N. Engl. J. Med. 362(19), 1846–1848 (2010).
   PubMed Web of Science ®Google Scholar
• Gatta-Cherifi B, Chabre O, Murat A et al. Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d'etude des Tumeurs Endocrines database. Eur. J. Endocrinol. 166(2), 269–279 (2012).
   PubMedGoogle Scholar
• Griniatsos JE, Dimitriou N, Zilos A et al. Bilateral adrenocortical carcinoma in a patient with multiple endocrine neoplasia type 1 (MEN1) and a novel mutation in the MEN1 gene. World J. Surg. Oncol. 9, 6 (2011).
   PubMedGoogle Scholar
• Haase M, Anlauf M, Schott M et al. A new mutation in the menin gene causes the multiple endocrine neoplasia type 1 syndrome with adrenocortical carcinoma. Endocrine 39(2), 153–159 (2011).
   PubMedGoogle Scholar
• Berna MJ, Annibale B, Marignani M et al. A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger – Ellison syndrome: identification of risk factors. J. Clin. Endocrinol. Metab. 93(5), 1582–1591 (2008).
   PubMed Web of Science ®Google Scholar
• Otake Y, Aoki M, Nakanishi T, Hashimoto K. Atypical carcinoid of thymus associated with multiple endocrine neoplasia syndrome type 1. Gen. Thorac. Cardiovasc. Surg. 58(10), 534–537 (2010).
   PubMedGoogle Scholar
• Ghazi AA, Dezfooli AA, Mohamadi F et al. Cushing syndrome secondary to a thymic carcinoid tumor due to multiple endocrine neoplasia type 1. Endocr. Pract. 17(4), e92–e96 (2011).
   Google Scholar
• Boix E, Picó A, Pinedo R, Aranda I, Kovacs K. Ectopic growth hormone-releasing hormone secretion by thymic carcinoid tumour. Clin. Endocrinol. 57(1), 131–134 (2002).
   PubMedGoogle Scholar
• Montero C, Sanjuán P, Fernández Mdel M, Vidal I, Verea H, Cordido F. [Bronchial carcinoid and type 1 multiple endocrine neoplasia syndrome. A case report]. Arch. Bronconeumol. 46(10), 559–561 (2010).
   PubMedGoogle Scholar
• Seigne C, Fontanière S, Carreira C et al. Characterisation of prostate cancer lesions in heterozygous Men1 mutant mice. BMC Cancer 10, 395 (2010).
   PubMedGoogle Scholar
• Imachi H, Murao K, Dobashi H et al. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance. Breast Cancer Res. Treat. 122(2), 395–407 (2010).
   PubMedGoogle Scholar
• Papi L, Palli D, Masi L et al. Germline mutations in MEN1 and BRCA1 genes in a woman with familial multiple endocrine neoplasia type 1 and inherited breast-ovarian cancer syndromes: a case report. Cancer Genet. Cytogenet. 195(1), 75–79 (2009).
   PubMedGoogle Scholar
• Dreijerink KM, Varier RA, van Beekum O et al. The multiple endocrine neoplasia type 1 (MEN1) tumor suppressor regulates peroxisome proliferator-activated receptor gamma-dependent adipocyte differentiation. Mol. Cell. Biol. 29(18), 5060–5069 (2009).
   PubMedGoogle Scholar
• Rusconi D, Valtorta E, Rodeschini O et al. Combined characterization of a pituitary adenoma and a subcutaneous lipoma in a MEN1 patient with a whole gene deletion. Cancer Genet. 204(6), 309–315 (2011).
   PubMedGoogle Scholar
• Nord KH, Magnusson L, Isaksson M et al. Concomitant deletions of tumor suppressor genes MEN1 and AIP are essential for the pathogenesis of the brown fat tumor hibernoma. Proc. Natl Acad. Sci. USA 107(49), 21122–21127 (2010).
   PubMedGoogle Scholar
• van Wijk JP, Dreijerink KM, Pieterman CR, Lips CJ, Zelissen PM, Valk GD. Increased prevalence of impaired fasting glucose in MEN1 gene mutation carriers. Clin. Endocrinol. 76(1), 67–71 (2011).
   Google Scholar
• Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in Type 2 diabetes. A systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 92(6), 2017–2029 (2007).
   PubMed Web of Science ®Google Scholar
• Kayaniyil S, Vieth R, Retnakaran R et al. Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for Type 2 diabetes. Diabetes Care 33(6), 1379–1381 (2010).
   PubMed Web of Science ®Google Scholar
• Newey PJ, Thakker RV. Role of multiple endocrine neoplasia type 1 mutational analysis in clinical practice. Endocr. Pract. 17(Suppl. 3), 8–17 (2011).
   PubMedGoogle Scholar
• Ramundo V, Milone F, Severino R et al. Clinical and prognostic implications of the genetic diagnosis of hereditary NET syndromes in asymptomatic patients. Horm. Metab. Res. 43(11), 794–800 (2011).
   PubMedGoogle Scholar
• Farrell WE, Azevedo MF, Batista DL et al. Unique gene expression profile associated with an early-onset multiple endocrine neoplasia (MEN1)-associated pituitary adenoma. J. Clin. Endocrinol. Metab. 96, 1905–1914 (2011).
   Google Scholar
• White HD, Blair J, Pinkney J et al. Improvement in the care of multiple endocrine neoplasia type 1 through a regional multidisciplinary clinic. QJM 103(5), 337–345 (2010).
   PubMedGoogle Scholar
• Goudet P, Murat A, Binquet C et al. Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. World J. Surg. 34(2), 249–255 (2010).
   PubMed Web of Science ®Google Scholar
• Lietman SA. Preimplantation genetic diagnosis for hereditary endocrine disease. Endocr. Pract. 17(Suppl. 3), 28–32 (2011).
   PubMedGoogle Scholar
• Luzi E, Brandi ML. Are microRNAs involved in the endocrine-specific pattern of tumorigenesis in multiple endocrine neoplasia type 1? Endocr. Pract. 17(Suppl. 3), 58–63 (2011).
   PubMedGoogle Scholar
• Luzi E, Marini F, Tognarini I et al. Ribozyme-mediated compensatory induction of menin-oncosuppressor function in primary fibroblasts from MEN1 patients. Cancer Gene Ther. 17(11), 814–825 (2010).
   PubMed Web of Science ®Google Scholar